BRIEF-CTI Biopharma announces removal of full clinical hold on Pacritinib

* Response submission included final clinical study reports for PERSIST-1,2 trials; dose-exploration clinical trial protocol FDA requested
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.